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Cord blood has been investigated as an alternative source for hematopoietic stem cell transplantation, but
information about its use for multiple myeloma is limited. The purpose of this study was to evaluate the
feasibility of cord blood transplantation (CBT) for patients with multiple myeloma. Eighty-six patients with
multiple myeloma who underwent a ﬁrst CBT between 2001 and 2011 were included in this retrospective
study. Sixty-two of them had received other types of stem cell transplantation before CBT. The cumulative
incidences of neutrophil engraftment at day 50, grade II to IV acute graft-versus-host disease (GVHD), and
chronic GVHD were 81.4%, 39.0%, and 19.5%, respectively. The incidence of nonrelapse mortality at 2 years was
39.0%, but it was only 6.2% in patients who underwent planned tandem autologous/reduced-intensity con-
ditioning CBT (auto/RIC-CBT). Progression-free survival (PFS) and overall survival (OS) at 6 years were 13.0%
and 15.2%, respectively. Less than a partial response before CBT and lack of prior transplantation were in-
dependent signiﬁcant adverse factors for PFS, whereas the presence of prior transplantation and planned
tandem transplantation were associated with better OS. OS at 6 years in patients who underwent auto/RIC-
CBT was 45.9%. In addition, the development of chronic GVHD was associated with superior PFS. In
conclusion, we demonstrated that cord blood is feasible as an alternative graft source for myeloma patients.
Although CBT provided long-term survival for a fraction of patients, optimal use of this graft requires further
clinical studies.
 2015 American Society for Blood and Marrow Transplantation.dgments on page 1297.
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ty for Blood and Marrow Transplantation.INTRODUCTION
Multiple myeloma remains incurable, although autolo-
gous hematopoietic stem cell transplantation (auto-HCT)
and novel agents such as thalidomide, lenalidomide, and
Table 1
Patient Characteristics
Characteristic Value
Age at transplantation, median (range), yr 55.5 (33-70)
Patient sex
Male 52 (60)
Female 34 (40)
Myeloma subtype
IgG 40 (47)
IgA 16 (19)
IgD 6 (7)
Light-chain 19 (22)
Nonsecretory 1 (1)
Data missing 4 (5)
Durie-Salmon stage at diagnosis
I 12 (14)
II 12 (14)
III 58 (67)
Data missing 4 (5)
ISS stage at diagnosis
I 17 (20)
II 22 (26)
III 18 (21)
Data missing 29 (34)
Cytogenetic abnormalities at diagnosis
Adverse* 14 (16)
13/del(13q) 12 (14)
Del(17p) 1 (1)
t(4;14) 1 (1)
Others 15 (17)
Normaly 42 (49)
Not performed/not reported 15 (17)
Use of novel drugs
Yes 36 (42)
Thalidomide 27 (31)
Bortezomib 20 (23)
Lenalidomide 4 (5)
No 38 (44)
Data missing 12 (14)
Prior transplantationz
0 24 (28)
1 47 (55)
2 13 (15)
3 2 (2)
Planned tandem transplantation
Yes 17 (20)
No 69 (80)
Response at transplantation
CR 3 (3)
VGPR 7 (8)
PR 23 (27)
SD 12 (14)
PD 38 (44)
Data missing 3 (3)
HLA compatibility in the GVH direction
Matched 7 (8)
1 Antigen mismatch 30 (35)
2 Antigen mismatch 47 (55)
3 Antigen mismatch 2 (2)
HLA compatibility in the HVG direction
Matched 5 (6)
1 Antigen mismatch 33 (38)
2 Antigen mismatch 46 (54)
More than 3 antigen mismatch 2 (2)
Conditioning regimen, n (%)
Myeloablative 8 (9)
Reduced-intensity 77 (90)
FLUþMEL 33 (38)
FLUþCY 19 (22)
FLUþBU 19 (22)
Other regimen 6 (7)
Unclassiﬁable 1 (1)
GVHD prophylaxis
Cyclosporine-based 49 (57)
Tacrolimus-based 35 (41)
Others 2 (2)
(Continued on next page)
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[1]. Allogeneic hematopoietic stem cell transplantation (allo-
HCT) is a potentially curative therapy for multiple myeloma
because it provides a tumor-free graft and a graft-versus-
myeloma (GVM) effect [2-6]. However, allo-HCT is not
considered a standard therapy because it is associated with a
high incidence of treatment-related mortality (TRM).
Although reduced-intensity conditioning (RIC) regimens
have reduced TRM to approximately 10% to 30% [4,5,7-13],
prospective studies on RIC allo-HCT did not show that it
offered an absolute advantage over tandem auto-HCT with
respect to progression-free survival (PFS) and overall survival
(OS) [14,15]. A possible explanation for this lack of a signiﬁ-
cant advantage of tandem auto/RIC allo-HCT may be the
insufﬁcient follow-up duration, as studies with long-term
observation showed better survival with tandem auto/RIC
allo-HCT than with auto-HCT alone [7,10].
In these prospective clinical trials, a human leukocyte an-
tigen (HLA)-identical sibling has been exclusively used as a
donor for allo-HCT. On the other hand, recent retrospective
surveys have shown that unrelated donors are being increas-
ingly used as alternative donors for myeloma patients [13,16].
However, information onunrelated cord blood transplantation
(CBT) for multiple myeloma has been limited to several case
reports [17-20]. Unrelated cord bloodhas been established as a
feasible alternative graft source for acute leukemia [21,22]. The
major advantages of CBTare the rapid availability of a graft and
the low risk of severe acute and chronic graft-versus-host
disease (GVHD), even in the presence of an HLA mismatch,
whereas the disadvantages of CBTare delays in neutrophil and
platelet recovery and a high incidence of graft failure [21-24].
Cord blood may be a useful source for patients with multiple
myelomaas it isdifﬁcult toﬁndasuitablesiblingdonorbecause
of the high patient age and because the reduction of severe
GVHD may decrease TRM. Therefore, we conducted a retro-
spective study using national registry data on multiple
myeloma patients who underwent CBT.
METHODS
Patients
Patients with multiple myeloma who underwent a ﬁrst single unit CBT
between 2001 and 2011 were included in this study. Clinical data for these
patients were obtained from the Transplant Registry Uniﬁed Management
Program (TRUMP) [25], which includes data from the Japan Cord Blood Bank
Network and the Japan Society for Hematopoietic Cell Transplantation
(JSHCT). The following patients were excluded: 3 patients with primary
plasma cell leukemia; 2 patients who lacked sufﬁcient data on diagnosis,
conditioning regimen, engraftment, GVHD, and so on; and 1 patient who
received salvage CBT for graft failure after allogeneic bone marrow trans-
plantation. Finally, 86 patients were eligible for the study. Next, we con-
ducted a secondary survey to obtain important information on the
transplantation outcomes, such as the response and progression on the basis
of the International MyelomaWorking Group uniform response criteria [26]
and the use of novel agents (thalidomide, bortezomib, and lenalidomide),
which was not included in, or was only insufﬁciently described in, the
TRUMP data. This study was planned by the Multiple Myeloma Working
Group of JSHCT and approved by the data management committees of
TRUMP, the ethical review board of JSHCT, and the institutional review board
of Saitama Medical Center, Jichi Medical University.
Endpoints and Deﬁnitions
The primary endpoint was overall survival after CBT. Secondary end-
points were the cumulative incidences of neutrophil and platelet engraft-
ment, acute and chronic GVHD, nonrelapse mortality (NRM) and PFS.
Neutrophil recovery was deﬁned as an absolute neutrophil count of at least
500 cells/mm3 for 3 consecutive days after transplantation. Platelet recovery
was deﬁned as an absolute platelet count of at least 5  104 cells/mm3
without platelet transfusion. Acute and chronic GVHD were graded ac-
cording to previously published criteria [27,28]. The incidence of chronic
GVHDwas evaluated in patients who survived for at least 100 days.NRMwas
Table 1
(continued)
Characteristic Value
Infused nucleated cells, median (range), 107/kg 2.59 (1.39-4.50)
Year at transplantation
2001-2005 51 (59)
2006-2011 35 (41)
ISS indicates International Staging System; del, deletion; CR, complete
response; VGPR, very good partial response; SD, stable disease; PD, pro-
gressive disease; GVH, graft-versus-host; HVG, host-versus-graft; FLU, ﬂu-
darabine; MEL, melphalan; CY, cyclophosphamide; BU, busulfan.
Data presented are n (%), unless indicated otherwise.
* Adverse cytogenetic abnormalities were deﬁned as any of the
following: 13/del (13q) by conventional metaphase cytogenetics, or
t(4;14), t(14;16), or del(17p) by conventional metaphase cytogenetics or
ﬂuorescein in situ hybridization (FISH).
y FISH analyses were not performed for most patients.
z Two patients received allogeneic transplantation and the others
received only autologous transplantation.
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deﬁned as survival without disease progression. Treatment response and
disease progression were evaluated according to the International Myeloma
Working Group uniform response criteria [26]. We classiﬁed the condi-
tioning regimen as either myeloablative or reduced-intensity according to
the National Marrow Donor Program/Center for International Blood and
Marrow Transplant Research operational deﬁnitions [29]. Adverse cytoge-
netic abnormalities at diagnosis were deﬁned as any of the following; 13/
del(13q) by conventional metaphase cytogenetics, or t(4;14), t(14;16), or
del(17p) by conventional metaphase cytogenetics or ﬂuorescein in situ
hybridization.A
B
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The probabilities of OS and PFS were estimated according to the Kaplan-
Meier method and compared among groups with the log-rank test. The
probabilities of neutrophil and platelet engraftment, acute and chronic
GVHD, and NRM were estimated on the basis of cumulative incidence
methods, and compared among groups with the Gray test, considering
death without engraftment for neutrophil and platelet engraftment, death
or progression without GVHD for acute and chronic GVHD, and death
without progression or relapse for NRM as competing events [30,31]. Of the
total 86 patients, 9 were excluded from the analyses of NRM or PFS because
of missing data. Multivariate analyses for OS and PFS were performed using
the Cox proportional hazards model, whereas multivariate analysis for NRM
was performed using the Fine and Gray regressionmodel [32]. The following
variables were considered: age at transplantation (50 or >50), patient sex,
myeloma subtype, cytogenetic abnormalities (adverse or others), use of
novel agents, number of prior transplantations (0, 1, or2), planned tandem
transplantation, response at transplantation (partial response [PR] or
<PR), HLA compatibility, conditioning regimen (myeloablative or reduced-
intensity), GVHD prophylaxis (cyclosporine-based or tacrolimus-based),
and year at transplantation (2001 to 2005 or 2006 to 2011). The develop-
ment of acute and chronic GVHD were treated as time-dependent cova-
riates. Variables with P values of .10 or less in the univariate analysis were
included in the multivariate model and were deleted in a stepwise manner
from the model to exclude factors with a P value of .05 or higher. All P values
were 2 sided and P values of .05 or less were considered statistically sig-
niﬁcant. All statistical analyses were performed with EZR (Saitama Medical
Center, Jichi Medical University) [33], which is a graphical user interface for
R (The R Foundation for Statistical Computing, version 3.0.2). More precisely,
it is a modiﬁed version of R commander (version 2.0-3) that was designed to
add statistical functions that are frequently used in biostatistics.0 20 40 60 80 100
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Figure 1. Cumulative incidences of neutrophil (A) and platelet engraftment (B).RESULTS
Patient Characteristics
The characteristics of the patients are shown in Table 1.
The total number of patients was 86 and the median age at
CBT was 55.5 years (range, 33 to 70). Thirty-three patients
were at least in PR (PR, very good partial response, or com-
plete response) before CBT, 50 patients were in stable disease
or progressive disease, and the remaining 3 were in un-
known disease status. Eight patients received myeloablative
regimens whereas the other 77 patients received RICregimens, except for 1 unclassiﬁable patient. Twenty-four of
the 86 patients had never received transplantation before
CBT, and 47 and 15 patients, respectively, had received
transplantation once and at least twice. Most of the prior
transplantations were auto-HCT. Only 2 patients had
received allo-HCT before CBT, and CBT was performed for
progressive disease after allo-HCT, rather than as salvage
transplantation for graft failure. Seventeen patients under-
went planned tandem auto/RIC-CBT.
Neutrophil and Platelet Engraftment
The cumulative incidence of neutrophil engraftment at
day 50 was 81.4% (95% conﬁdence interval (CI), 71.3% to
88.2%) (Figure 1A). The cumulative incidence of platelet
engraftment at day 100 was 53.1% (95% CI, 41.5% to 63.4%)
(Figure 1B).
Acute and Chronic GVHD
The cumulative incidences of grade II to IV and grade III
and IV acute GVHD at day 100 were 39.0% (95% CI, 28.4% to
49.5%) and 15.9% (95% CI, 8.9% to 24.6%), respectively
(Figure 2A and B). The cumulative incidences of chronic
GVHD and extensive chronic GVHD at 3 years were 19.5%
(95% CI, 11.7% to 28.9%) and 9.5% (95% CI, 4.4% to 17.0%),
respectively (Figure 2C and D).
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Figure 2. Cumulative incidences of grade II to IV acute GVHD (A), grade III and IV acute GVHD (B), chronic GVHD (C), and extensive chronic GVHD (D).
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The cumulative incidence of NRM at 2 years was 39.0%
(95% CI, 28.0% to 49.7%) (Figure 3A). Themajor causes of NRM
were infection (30%), GVHD (13%), bleeding (13%), organ
failure (10%), graft failure (10%), thrombotic microangiopathy
(10%), veno-occlusive disease (3%), acute respiratory distress
syndrome (3%), and others (7%). A RIC regimen and planned
tandem auto/RIC-CBT were independent signiﬁcant factors
that decreased the incidence of NRM in the multivariate
analysis (hazard ratio [HR], .35; 95% CI, .13 to .93; P ¼ .036,
and HR, .12; 95% CI, .016 to .92; P ¼ .041) (Table 2). The cu-
mulative incidence of NRM at 2 years in patients who un-
derwent tandem auto/RIC-CBT was 6.2% (95% CI, .4% to
25.5%), which was lower than that in other patients (47.5%;
95% CI, 34.4% to 59.6%; P ¼ .004) (Figure 3B).
PFS and OS
The best responses after CBT are summarized in Table 2.
The response rate appeared inferior to those in previous
studies of allo-HCT. However, in an analysis that excluded 30
patients whowere unevaluable or who had data missing, the
overall response rate after CBT is about 80%. The probabilities
of PFS at 3 years and 6 years were 14.3% (95% CI, 7.6% to
23.0%) and 13.0% (95% CI, 6.7% to 21.5%), respectively
(Figure 3C). Less than PR before CBT and a lack of prior
transplantationwere independent signiﬁcant adverse factors
for PFS (HR, 1.78; 95% CI, 1.04 to 3.06; P ¼ .036, and HR, .36;
95% CI, .20 to .65; P< .001 for 1 prior transplantation, HR, .43;
95% CI, .20 to .94; P ¼ .033 for 2 prior transplantations)
(Table 3). The probabilities of PFS in patients who were in at
least PR before CBT and had received a prior transplantation
were higher than those in other patients (28.6%; 95% CI,13.5%to 45.6% versus 6.2%; 95% CI,1.6% to 15.5% at 3 years; P< .001)
(Figure 3D).
The probabilities of OS at 3 years and 6 years were 31.3%
(95% CI, 21.8% to 41.2%) and 15.2% (95% CI, 7.5% to 25.4%)
(Figure 3E). The independent signiﬁcant favorable prognostic
factors were prior transplantation (HR, .41; 95% CI, .23 to .74;
P ¼ .003 for 1 prior transplantation and HR, .34; 95% CI, .16 to
.73; P ¼ .006 for 2 prior transplantations) (Table 3) and
planned tandem auto/RIC-CBT (HR, .26; 95% CI, .11 to .62; P¼
.002). The probabilities of OS in patients who underwent
tandem auto/RIC-CBT were higher than those in patients
who did not undergo tandem transplantation (76.5%; 95% CI,
48.8% to 90.4% versus 19.9%; 95% CI, 11.4% to 30.2% at 3 years,
and 45.9%; 95% CI, 16.3% to 71.5% versus 7.5%; 95% CI, 2.3% to
16.9% at 6 years; P < .001) (Figure 3F). On the other hand,
adverse cytogenetic abnormalities and the use of novel
agents were not signiﬁcantly associated with PFS or OS. The
best outcome could be expected in patients who underwent
tandem auto/RIC-CBT and achieved at least PR before CBT.
The outcome was superior to the other patients, as shown in
Figure 3G and H, with OS and PFS at 6 years of 64.2% (95% CI,
33.3% to 83.6%) and 35.7% (95% CI, 13.0% to 59.4%),
respectively.
To assess the inﬂuence of acute or chronic GVHD on PFS
and OS, we performed analyses that treated the development
of acute and chronic GVHD as time-dependent covariates.
Acute GVHD was not signiﬁcantly associated with PFS or OS.
However, chronic GVHD was associated with a higher PFS
rate among patients who survived at least 100 days after CBT
(HR, .30; 95% CI, .11 to .79; P ¼ .015) (Table 4), although a
signiﬁcant association with OS was not observed in the
multivariate analysis. In a landmark analysis from day 150
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Figure 3. Nonrelapse mortality in 77 evaluable patients (A), comparison of CBT with and without planned tandem auto/RIC-CBT (B). Progression-free survival in 77
evaluable patients (C), comparison of CBT with and without favorable factors (more than PR before CBT and prior transplantation) (D). Overall survival in 86 patients
(E), comparison of CBT with and without planned tandem auto/RIC-CBT (F). Overall survival in 86 patients (G) and progression-free survival in 77 evaluable patients
(H), comparison of CBT with planned tandem auto/RIC-CBT for patients with response of more than PR before CBT and all others.
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Table 2
Best Response after Cord Blood Transplantation
Response at
Transplantation
n Best Response after Transplantation n
CR 3 CR 2
Unevaluated/data missing 1
VGPR 7 VGPR 4*
PD 1
Unevaluated/data missing 2
PR 23 sCR 2
CR 7
VGPR 6*
PR 2
SD 1
PD 1
Unevaluated/data missing 4
SD 12 CR 3
PR 5
SD 1
Unevaluated/data missing 3
PD 38 CR 11
VGPR 1
PR 2
SD 3
PD 4
Unevaluated/data missing 17
Data missing 3 Data missing 3
sCR indicates stringent complete response.
* One patient was at least VGPR (immunoﬁxation not performed).
Table 4
Inﬂuence of Acute or Chronic GVHD on PFS and OS
Univariate HR (95% CI) P Value
PFS
Acute GVHD
Grade 0-I 1.00
Grade II-IV .85 (.51-1.44) .552
Acute GVHD
Grade 0-II 1.00
Grade III-IV 1.28 (.66-2.47) .465
Chronic GVHD
No 1.00
Yes .35 (.14-.89) .0282
OS
Acute GVHD
Grade 0-I 1.00
Grade II-IV .88 (.52-1.48) .632
Acute GVHD
Grade 0-II 1.00
Grade III-IV 1.45 (.75-2.79) .271
Chronic GVHD
No 1.00
Yes .45 (.20-1.04) .060
Multivariate
PFS
Chronic GVHD
Yes 1.00
No .30 (.11-.79) .015
Prior transplantations, no.
0 1.00
1 .25 (.12-.54) <.001
2 .43 (.14-1.28) .129
K. Kawamura et al. / Biol Blood Marrow Transplant 21 (2015) 1291e12981296after CBT, PFS was signiﬁcantly prolonged in patients with
chronic GVHD (Figure 4).DISCUSSION
In this study, we evaluated the feasibility of cord blood as
an alternative graft source for allogeneic transplantation for
multiple myeloma. To our knowledge, this is the ﬁrst registry
database study to evaluate a relatively large number of pa-
tients with multiple myeloma who underwent CBT. The cu-
mulative incidences of neutrophil and platelet engraftment
after CBT for multiple myeloma were comparable to those
after CBT for other hematological malignancies in Japan
[22,23]. The cumulative incidence of NRM at 2 years wasTable 3
Multivariate Analysis of NRM, PFS, and OS
Outcome HR (95% CI) P Value
NRM
Conditioning regimen
Myeloablative 1.00
Reduced-intensity .35 (.13-.93) .036
Planned tandem transplantation
No 1.00
Yes .12 (.016-.92) .041
PFS
Response at transplantation
PR 1.00
<PR 1.78 (1.04-3.06) .036
Prior transplantation, no.
0 1.00
1 .36 (.20-.65) <.001
2 .43 (.20-.94) .033
OS
Prior transplantation, no.
0 1.00
1 .41 (.23-.74) .003
2 .34 (.16-.73) .006
Planned tandem transplantation
No 1.00
Yes .26 (.11-.62) .00239.0%, which was higher than that in recent studies on RIC
allo-HCT for myeloma [4,7-13,16]. However, 8 (9%) patients
who received myeloablative conditioning regimens contrib-
uted to the higher NRM. In addition, a smaller proportion of
the current cohort compared to previous studies had ach-
ieved complete response and PR before CBT (only 3% and
38%, respectively). Furthermore, most of the 62 patients who
underwent auto-HCT before CBT, excluding planned tandem
auto/RIC-CBT, underwent CBT because of relapse or pro-
gression after prior auto-SCT. On the other hand, only 3 of the
24 patients who had never received a transplantation before
CBT had achieved at least PR before CBT. Bortezomib,0 2 4 6 8 10
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Figure 4. Progression-free survival grouped according to the development of
chronic GVHD by a landmark analysis at day 150 after cord blood
transplantation.
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2009, and 2010, respectively, in Japan, and thus, many pa-
tients received CBT despite an insufﬁcient response to prior
treatments. In particular, about 80% of patients without prior
transplantation underwent CBT before the new agents
became available. The lack of a sufﬁcient response at CBT
may have increased NRM. In fact, the cumulative incidence of
NRM at 2 years in patients who underwent planned tandem
auto/RIC-CBT was only 6.2% (Figure 3B). Therefore, unrelated
cord blood can be considered to be an alternative graft source
for patients with multiple myeloma, who lack appropriate
bone marrow transplant (BMT) or peripheral blood stem cell
transplant (PBSCT) donors.
Overall, although neither PFS nor OS were encouraging,
some patients achieved long-term disease-free survival after
CBT. In the multivariate analyses, a response to prior treat-
ment and the presence of prior transplantation (auto-HCT)
were signiﬁcantly associated with PFS, and the presence of
prior transplantation and planned tandem auto/RIC-CBT
were signiﬁcantly associated with OS. However, the appli-
cation of this tandem auto/RIC-CBT should be cautiously
considered, as several previous studies did not show a sur-
vival beneﬁt of tandem auto-allo-HCT from an HLA-matched
sibling donor over tandem auto-HCT. Although high-risk
karyotypes did not inﬂuence PFS or OS, the statistical po-
wer was limited due to the small number of patients with
high-risk karyotypes.
The major advantage of allo-HCT is a GVM effect. The
existence of a GVM effect was demonstrated by remission
that occurred after donor lymphocyte infusion in patients
with relapsed multiple myeloma who had received allo-HCT
[2,3]. In addition, some previous studies have shown that
chronic GVHD is associated with favorable PFS and OS [4-6].
For example, Crawley et al. reported that chronic GVHD was
associated with better PFS and OS for 229 patients who
received RIC-allo in an European Society for Blood and
Marrow Transplantation registry data analysis. In the present
study, chronic GVHD was a signiﬁcant predictive factor for
prolonged PFS. On the other hand, the persistence of chronic
GVHDmay inﬂuence late complications and quality of life. In
general, CBT decreases chronic GVHD compared with BMTor
PBSCT [21-24]. In fact, the incidence of chronic GVHD in the
current study was lower than those in previous studies on
BMT or PBSCT for myeloma [4-6,13].
For patients with a higher risk for progression after CBT,
strategies to intensify the GVM effect may be required. More
than one half of the patients who were in less than PR before
CBT showed a better response after CBT (Table 2) but the
duration of the response was relatively short. Although
prophylactic donor lymphocyte infusion is a possible strat-
egy for intensifying the GVM effect, it is not available after
CBT. Another approach is maintenance treatment with
lenalidomide. Lenalidomide is an immunomodulatory drug
with direct antimyeloma and immunostimulatory effects,
such as an increase in activated natural killer and T cells [34],
and it is already used as an effective maintenance treatment
after auto-HCT [35,36]. On the other hand, maintenance
treatment with lenalidomide after allo-HCT also improved
the degree of the treatment response for some patients, but
an increase in acute GVHD was a critical problem [37-39].
Further studies are ongoing to determine its suitable dose
and timing.
This study has some limitations. First, the retrospective
nature of this study precluded the precise evaluation of
treatment strategies with respect to the outcome of CBT.Second, ﬂuorescein in situ hybridization analyses are not
routinely performed in Japan because of issues with insur-
ance coverage. Therefore, karyotype classiﬁcation was not
sufﬁciently performed. Finally, this study included patients
with heterogeneous backgrounds, and therefore the statis-
tical power in each subgroup analysis was limited.
In conclusion, we demonstrated that cord blood is a
feasible alternative graft source for allogeneic trans-
plantation for multiple myeloma. Although CBT provided
long-term survival for a fraction of patients, further clinical
studies will be needed to identify the optimal use of this
graft. In addition, strategies to enhance a GVM effect after
CBT should be investigated to decrease disease progression.
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